Investors

Investors2018-12-04T14:56:54+00:00

IXICO CEO Giulio Cerroni on record revenues and significant contract extension

Giulio Cerroni, chief executive of IXICO PLC (LON:IXI), caught up with Proactive London’s Andrew Scott to discuss their results for the year to the end of September as well as the expansion to a contract.

The scope of a current contract with a top 10 biopharmaceutical company has been enlarged, increasing the value by US$2.4mln over the remaining six-year term of the agreement to US$5.1mln.

Where IXICO’s results are concerned revenue rose 32% to £5.39mln from £4.10mln the year before, while the gross margin improved to 58.8% from 56.4%.

The loss before tax narrowed to £793,000 from £1.91mln the previous year.

IXICO full year performance expected to be ‘ahead of market expectations’

Giulio Cerroni, Chief Executive Officer of IXICO, said:

“Performance for the current financial year is now expected to be “ahead of market expectations”.  Reported revenue for the full year is expected to be at least £5.1mln, a 24% increase on the previous year.”

IXICO sees strong topline growth in interim results, 23 May 2018

Giulio Cerroni, Chief Executive Officer of IXICO, said:

“The company is seeing topline growth of 30% in a strong set of interim results. The company is also seeing improvements in its gross margins and cash position. He adds that the company recently raised £5.5mln through an oversubscribed placing, and has brought some new institutional investors on board.”

IXICO  Interim Results 2018 Webcast

IXICO’s leadership team announces strong interim results, outlines its plans for future investment with the proceeds of the recent capital raise, and describes the significance of its recently commercialised digital technology products.

Five-point plan to scale business in a bid to deliver double digit revenue growth, 28 November 2017

Giulio Cerroni, Chief Executive Officer of IXICO, said:

“I have set out a commercially-led growth plan to deliver top-line growth.  We will build on IXICO’s trusted position in providing neuro-imaging technology enabled specialist services to the biopharmaceutical industry across three key value segments:

  • Selecting patients for clinical trials;
  • Assessing safety and efficacy in every phase of drug development; and
  • Post marketing surveillance of marketed medicines.”
AIM RULE 26
CONTACTS & ADVISeRS
SHARE PRICE
RNS ANNOUNCEMENTS
SHAREHOLDER INFORMATION
GOVERNANCE
COMPANY DOCUMENTS
FINANCIAL CALENDAR

To speak to one of our experts and find out more

CONTACT US